Evaluation of the Vascutek Hybrid Graft for Use in the Replacement of the Aortic Arch and Concomitant Treatment of an Aneurysm/Dissection of the Descending Aorta in the Frozen Elephant Trunk Procedure
Launched by VASCUTEK LTD. · Feb 23, 2012
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The Vascutek Hybrid device is designed for use during a frozen elephant trunk procedure. Each system is comprised of a fully sealed traditional prosthesis which is stented at the distal end. A minimum of 10 and a maximum of 30 patients with aneurysmal disease of the ascending aorta, the arch and the proximal descending aorta will receive a hybrid prosthesis implanted without the use of the delivery system and a minimum of 10 patients and a maximum of 20 patients will be implanted with a hybrid device using the delivery system.
The traditional prosthesis component is representative of curre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with aneurysm and/or dissection of the aortic arch and/or descending aorta
- • 2. Patient must have agreed to participate voluntarily and have signed and dated an Ethics Committee approved Patient Informed Consent
- • 3. Patient is able and willing to comply with the protocol and associated follow-up requirements
- Exclusion Criteria:
- • 1. Patients unfit for open surgical repair involving circulatory arrest
- • 2. Endocarditis or active infective disorder of the aorta
- • 3. Patients unwilling to give informed consent
About Vascutek Ltd.
Vascutek Ltd. is a leading medical device company specializing in the development and manufacturing of innovative vascular grafts and associated technologies. With a commitment to advancing patient care, Vascutek is dedicated to providing high-quality, reliable solutions for the treatment of vascular diseases. The company's extensive expertise in biomaterials and surgical techniques underpins its clinical trials aimed at evaluating the safety and efficacy of its products. Vascutek's mission is to enhance surgical outcomes and improve the quality of life for patients worldwide through rigorous research, collaboration, and adherence to the highest standards of regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials